64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression

Journal of Nuclear Medicine

Volumn 48, Issue 7, 2007, Pages 1162-1171

  Li, Zi Bo ^a   Cai, Weibo ^a   Cao, Qizhen ^a   Chen, Kai ^a   Wu, Zhanhong ^a   He, Lina ^a   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

64Cu; Integrin v 3; Positron emission tomography (PET); RGD multimer; Tumor angiogenesis

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ARGINYLGLYCYLASPARTIC ACID COPPER 64; ARGINYLGLYCYLASPARTIC ACID; COPPER 64; GLUTAMIC ACID; TETRAMER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER MODEL; CELL ADHESION; CONTROLLED STUDY; DEVICE; DRUG ACCUMULATION; DRUG STRUCTURE; DRUG UPTAKE; FEMALE; GLIOBLASTOMA; IC 50; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; KIDNEY; KINETICS; MOLECULAR SIZE; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUDE MOUSE; PEPTIDE SYNTHESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR XENOGRAFT;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; COPPER RADIOISOTOPES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34447336118     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.039859     Document Type: Article

References (40)

1. 3 angiogenesis. Science. 1994;264:569-571.
2. Polverini PJ. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. J Dent Educ. 2002;66:962-975.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
4. 3 chain of type IV collagen, modifies endothelial cell function and inhibits angiogenesis. Connect Tissue Res. 2004;45:151-163.
5. Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res. 2004;117:307-336.
6. 3 integrin receptors in breast tumor. J Exp Clin Cancer Res. 2001;20:585-590.
7. v integrins. Science. 1995;270:1500-1502.
8. 3 integrin "vitronectin receptor." Int J Biochem Cell Biol. 1997;29:721-725.
9. 5 integrin expression in glioma periphery discussion 390. Neurosurgery. 2001;49:380-389.
10. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90;561-565.
11. 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4:123-131.
12. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000-2007.
13. 2. J Nucl Med. 2006;47:113-121.
14. v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs. 2003;4:722-731.
15. 3 integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34:267-273.
16. 111In-labeled RGD peptide. Nucl Med Biol. 2007;34:29-35.
17. 18F-galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333-1341.
18. Sharma SD, Jiang J, Hadley ME, Bentley DL, Hruby VJ. Melanotropic peptide-conjugated beads for microscopic visualization and characterization of melanoma melanotropin receptors. Proc Natl Acad Sci U S A. 1996;93:13715-13720.
19. Mammen M, Chio S-K, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed Engl. 1998;37:2755-2794.
20. 64Cu-labeled tetrameric RGD peptide. J Nucl Med. 2005;46:1707-1718.
21. 3 targeted radiotracers for tumor imaging. Mol Pharm. 2006;3:472-487.
22. Ye Y, Bloch S, Xu B, Achilefu S. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006;49:2268-2275.
23. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 2001;12:624-629.
24. Thumshirn G, Hersel U, Goodman SL, Kessler H. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chem Eur J. 2003;9:2717-2725.
25. Boturyn D, Coll J-L, Garanger E, Favrot M-C, Dumy P. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. J Am Chem Soc. 2004;126:5730-5739.
26. Dirksen A, Langereis S, de Waal BFM, van Genderen MHP, Hackeng TM, Meijer EW. A supramolecular approach to multivalent target-specific MRI contrast agents for angiogenesis. Chem Commun (Camb). 2005;2811-2813.
27. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem. 2006;49:6087-6093.
28. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988;54:105-115.
29. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715.
30. Ogata T, Teshima T, Kagawa K, et al. Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res. 2005;65:113-120.
31. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326-336.
32. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
33. 3 integrin expression. J Nucl Med. 2006;47:1172-1180.
34. 3 antagonists as radiopharmaceuticals for tumor radiotherapy. Top Curr Chem. 2005;252:193-216.
35. 3 integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146-6151.
36. Janssen M, Frielink C, Dijkgraaf I, et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm. 2004;19:399-404.
37. Poethko T, Schottelius M, Thumshirn G, et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochimica Acta. 2004;92:317-327.
38. 2. J Nucl Med. 2006;47:113-121.
39. 111In-octreotide in mice and rats. J Nucl Med. 2006;47:528-533.
40. Hamerski DA, Santoro SA. Integrins and the kidney: biology and pathobiology. Curr Opin Nephrol Hypertens. 1999;8:9-14.